Table 2.

Hemorrhagic events during the 60-day study period according to initial anticoagulation strategy

Hemorrhage characteristics	Full-dose (n = 75)	Modified-dose (n = 33)	None (n = 13)
Total hemorrhage, n (%)	18 (24)	5 (15)	0
Severity of hemorrhage, n (%)
Fatal hemorrhage	1 (1)	0	0
Major hemorrhage	8 (11)	2 (6)	0
Clinically relevant nonmajor hemorrhage	9 (12)	2 (6)	0
Minor hemorrhage	0	1 (3)	0
Type of hemorrhage
Intracranial hemorrhage	2 (3)	1 (3)	0
Ocular	0	1 (3)	0
Upper gastrointestinal bleed	1 (1)	0	0
Lower gastrointestinal bleed	7 (9)	1 (3)	0
Retroperitoneal	1 (1)	0	0
Hematuria	4 (5)	0	0
Mucocutaneous	4 (5)	2 (6)	0
Intramuscular	1 (1)	0	0
Anticoagulant dose at time of hemorrhage
Full-dose	15 (20)	4 (12)	—
Modified-dose	3 (4)	1 (3)	—
None	1 (1)	0	—
Anticoagulant at time of hemorrhage
LMWH	10 (13)	2 (6)	—
Unfractionated heparin	4 (5)	1 (3)	—
Direct oral anticoagulant	4 (5)	2 (6)	—
Median days with platelet count <100 000/µL	20	16	20